Join Growin Stock Community!

Natera, inc.NTRA.US Overview

US StockHealthcare
(No presentation for NTRA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NTRA AI Insights

NTRA Overall Performance

NTRA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NTRA Recent Performance

-3.76%

Natera, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NTRA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NTRA Key Information

NTRA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NTRA Profile

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Price of NTRA

NTRA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NTRA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.58
PB Ratio
23.17
Price-to-FCF
255.82
METRIC
VALUE
vs. INDUSTRY
Gross Margin
64.75%
Net Margin
-9.03%
Revenue Growth (YoY)
35.90%
Profit Growth (YoY)
45.94%
3-Year Revenue Growth
45.23%
3-Year Profit Growth
70.44%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
12.58
PB Ratio
23.17
Price-to-FCF
255.82
Gross Margin
64.75%
Net Margin
-9.03%
Revenue Growth (YoY)
35.90%
Profit Growth (YoY)
45.94%
3-Year Revenue Growth
45.23%
3-Year Profit Growth
70.44%

  • When is NTRA's latest earnings report released?

    The most recent financial report for Natera, inc. (NTRA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NTRA's short-term business performance and financial health. For the latest updates on NTRA's earnings releases, visit this page regularly.

  • What is the operating profit of NTRA?

    According to the latest financial report, Natera, inc. (NTRA) reported an Operating Profit of -22.79M with an Operating Margin of -3.42% this period, representing a growth of 64.81% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NTRA's revenue growth?

    In the latest financial report, Natera, inc. (NTRA) announced revenue of 665.5M, with a Year-Over-Year growth rate of 39.79%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does NTRA have?

    As of the end of the reporting period, Natera, inc. (NTRA) had total debt of 198.8M, with a debt ratio of 0.08. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NTRA have?

    At the end of the period, Natera, inc. (NTRA) held Total Cash and Cash Equivalents of 1.08B, accounting for 0.45 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NTRA go with three margins increasing?

    In the latest report, Natera, inc. (NTRA) did not achieve the “three margins increasing” benchmark, with a gross margin of 66.9%%, operating margin of -3.42%%, and net margin of 7.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NTRA's profit trajectory and future growth potential.

  • Is NTRA's EPS continuing to grow?

    According to the past four quarterly reports, Natera, inc. (NTRA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.36. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NTRA?

    Natera, inc. (NTRA)'s Free Cash Flow (FCF) for the period is 37.82M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 8.77% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NTRA?

    The latest valuation data shows Natera, inc. (NTRA) has a Price-To-Earnings (PE) ratio of -141.65 and a Price/Earnings-To-Growth (PEG) ratio of -1.07. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.